within Pharmacolibrary.Drugs.ATC.P;

model P01CB01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 8.333333333333333e-07,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00020999999999999998,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00013000000000000002,
    k12             = 0.04,
    k21             = 0.04
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>P01CB01</td></tr><td>route:</td><td>intramuscular</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Meglumine antimonate is a pentavalent antimonial compound historically used in the treatment of leishmaniasis, a parasitic disease. It is administered parenterally and is no longer the first-line therapy in many settings due to toxicity and the development of newer drugs.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adults with cutaneous leishmaniasis after intramuscular administration.</p><h4>References</h4><ol><li><p>Valladares, JE, et al., &amp; Arboix, M (1997). Pharmacokinetics of liposome-encapsulated meglumine antimonate after intramuscular and subcutaneous administration in dogs. <i>The American journal of tropical medicine and hygiene</i> 57(4) 403–406. DOI:<a href=&quot;https://doi.org/10.4269/ajtmh.1997.57.403&quot;>10.4269/ajtmh.1997.57.403</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9347953/&quot;>https://pubmed.ncbi.nlm.nih.gov/9347953</a></p></li><li><p>Cruz, A, et al., &amp; Saravia, NG (2007). Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. <i>The Journal of infectious diseases</i> 195(4) 602–608. DOI:<a href=&quot;https://doi.org/10.1086/510860&quot;>10.1086/510860</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17230422/&quot;>https://pubmed.ncbi.nlm.nih.gov/17230422</a></p></li><li><p>Tassi, P, et al., &amp; Marcotrigiano, GO (1994). Pharmacokinetics of N-methylglucamine antimoniate after intravenous, intramuscular and subcutaneous administration in the dog. <i>Research in veterinary science</i> 56(2) 144–150. DOI:<a href=&quot;https://doi.org/10.1016/0034-5288(94)90096-5&quot;>10.1016/0034-5288(94)90096-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8191002/&quot;>https://pubmed.ncbi.nlm.nih.gov/8191002</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end P01CB01;
